EGFR and non-small cell lung carcinoma: In order to reduce the toxicity associated with the four‐drug regimen and treat NSCLC with rare EGFR mutations after TKI failure, sintilimab plus anlotinib represents a promising treatment choice after failure of standard of care treatment.